{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000067","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.602593+00:00","generated_at":"2026-06-15T04:32:05.761624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio Q1 net loss $57.1M; cash $223.9M; ITIL-306 phase 1 expected in 2H 2023","bullets":["Net loss of $57.1M ($0.44 per share) vs $54.1M ($0.42) in Q1 2022; restructuring charges of $24.6M.","Cash, equivalents, restricted cash and marketable securities $223.9M at Mar 31, 2023, down from $260.9M at Dec 31, 2022; runway beyond 2026.","ITIL-306 phase 1 study in UK anticipated to initiate in 2H 2023 after MHRA CTA clearance; initial data expected in 2024.","R&D expenses fell to $20.7M from $39.2M YoY; quarterly cash burn expected <$10M from 2H 2023 through end of 2024.","Consolidating R&D to UK; pursuing lease or sale of Tarzana, CA manufacturing facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000067","json":"https://secwatch.observer/filing/0001789769-23-000067.json","markdown":"https://secwatch.observer/filing/0001789769-23-000067.md","text":"https://secwatch.observer/filing/0001789769-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000067/0001789769-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000067/til-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:32:05.761624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b7e779383593beb905526d828245006223b279c","claim":"Instil Bio, Inc. reported quarter ended March 31, 2023 results: net income $ (57,068), EPS $ (0.44).","evidence_excerpt":"On May 11, 2023 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000067/0001789769-23-000067-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Net income","value":"$ (57,068)"},{"label":"EPS","value":"$ (0.44)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}